Organogenesis Holdings Inc.
Organogenesis develops, manufactures and sells regenerative medicine products for advanced wound care and surgical and sports medicine markets. Its customers include hospitals, wound care centers, government facilities, ambulatory surgery centers and physician offices. The Advanced Wound Care portfolio includes products for chronic and acute wounds, such as Apligraf, Dermagraft, PuraPly, CYGNUS, Affinity, Novachor, NuShield and SimpliMax. Surgical and sports medicine products include placental allografts and collagen matrices for surgical barriers, open-wound management and soft-tissue reinforcement. ReNu, a cryopreserved suspension derived from human amniotic membrane and amniotic-fluid cells, targets symptoms associated with knee osteoarthritis. Organogenesis sells primarily through its U.S. direct sales force, with independent agencies also serving the Surgical & Sports Medicine market. It provides in-house reimbursement, medical and technical support. The company manufactures primary non-placental products and uses third-party manufacturers for placental-based products. Its research and development activities take place in Canton, Massachusetts, Birmingham, Alabama, and San Diego, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ORGO in the last 30 days.
See all $ORGO insider activity →Organogenesis (ORGO) reported Q3 2026 revenue of $45.5M, down 70% YoY but up 6% QoQ. The company gained market share, with Apligraf and other products showing growth. Amnuvx BLA review delayed due to FDA requests. ORGO remains optimistic about its position in the skin substitute market and future growth.
Organogenesis reported Q3 cash of $26.9M, down from $94.3M in 2025. It expects 2026 revenue of $179M-$200M, a 65%-68% decline. The company plans $45M in annual cost reductions and $8M for FDA remediation. Amnuvx review and market stabilization were discussed. ORGO shares trade on NASDAQ.
Organogenesis Holdings Inc. reported a sharp YoY revenue decline in Q3 2026, but saw sequential improvement and market share gains. The company lowered its FY26 revenue guidance to $179M-$200M and extended the FDA review timeline for Amnuvx due to facility remediation.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning ORGO (Organogenesis Holdings Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 9 bearish.
Recent ORGO coverage spans earnings and financial news.
Earnings miss with steep YoY decline but modest sequential growth.
Guidance cut and remediation spend likely pressure the stock lower, though cost reductions may provide some floor.
Guidance reduction signals weaker near‑term demand, likely pressuring the stock.
The earnings miss and modest revenue outlook likely weigh on the stock.
The sharp revenue decline and net loss suggest continued pressure on the stock.
AlphAI scores every news story that mentions ORGO with an AI model for sentiment and relevance, and aggregates insider trades from Organogenesis Holdings Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Organogenesis (ORGO) reported Q3 2026 revenue of $45.5M, down 70% YoY but up 6% QoQ. The company gained market share, with Apligraf and other products showing growth. Amnuvx BLA review delayed due to FDA requests. ORGO remains optimistic about its position in the skin substitute market and future growth.
Organogenesis reported Q3 cash of $26.9M, down from $94.3M in 2025. It expects 2026 revenue of $179M-$200M, a 65%-68% decline. The company plans $45M in annual cost reductions and $8M for FDA remediation. Amnuvx review and market stabilization were discussed. ORGO shares trade on NASDAQ.
Organogenesis Holdings Inc. reported a sharp YoY revenue decline in Q3 2026, but saw sequential improvement and market share gains. The company lowered its FY26 revenue guidance to $179M-$200M and extended the FDA review timeline for Amnuvx due to facility remediation.
Organogenesis Holdings Inc. (ORGO) reported a Q3 loss of $32.8M, or 25 cents per share, with revenue of $45.5M. The company expects full-year revenue between $179.4M and $200M.
Organogenesis Holdings Inc. reported a 70% YoY revenue decline to $45.5M in Q3, with a $29.6M net loss and $(22.4)M Adjusted EBITDA. The company attributed the drop to Medicare market disruption and expects significant revenue declines to continue in Q4. Management believes available working capital and cash will support operations for at least 12 months.
Organogenesis Holdings Inc. reported a 70% YoY revenue decline in Q3, with losses replacing prior-year income. The company's Advanced Wound Care segment contributed most to the drop. FY 2026 guidance suggests a 65%–68% revenue decrease, with a gradual improvement expected in Q4.
Organogenesis Holdings Inc. (ORGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results CANTON, Mass., (November 5, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healin
Organogenesis Holdings Inc. (ORGO) reported a net loss of $29.6 million for Q3 2026, a decline from a net income of $21.6 million in Q3 2025. Revenue fell 70% to $45.5 million, with Advanced Wound Care products down 73% and Surgical & Sports Medicine products down 19%. The company expects full-year revenue to decline 65-68% from 2025. Management will discuss results in a conference call.
Organogenesis reported that a peer-reviewed study found its PuraPly AM product, combined with standard care, significantly improved 12-week wound closure in diabetic foot ulcers compared to standard care alone, according to the company.
Organogenesis Holdings Inc. (ORGO) will release its Q3 2026 financial results after market close on Nov. 5. A conference call is scheduled for 5 p.m. ET to discuss results and provide a corporate update. The webcast will be available live and archived on the company's website.
